Principle standards and problems regarding proof of efficacy in clinical psychopharmacology (Q37627217)

21 August 2017

title

Principle standards and problems regarding proof of efficacy in clinical psychopharmacology (English)

1 reference

21 August 2017

Hans-Jürgen Möller

1 reference

21 August 2017

Karl Broich

1 reference

21 August 2017

publication date

1 February 2010

1 reference

European Archives of Psychiatry and Clinical Neuroscience

21 August 2017

published in

1 reference

21 August 2017

volume

260

1 reference

21 August 2017

1 reference

21 August 2017

page(s)

3-16

1 reference

Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00406-009-0071-8

The rationale and ethics of medication-free research in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-009-0071-8

Three Alternatives to the Double-Bind

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-009-0071-8

Minimization: A new method of assigning patients to treatment and control groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-009-0071-8

Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials

21 January 2018

1 reference

12 December 2020

Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database

1 reference

12 December 2020

Clinical investigations into antidepressive mechanisms. I. Antihistaminic and cholinolytic effects: amitriptyline versus promethazine

1 reference

12 December 2020

The nature and power of the placebo effect

1 reference

12 December 2020

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

1 reference

12 December 2020

Phase IV research and drug utilization observation studies.

1 reference

12 December 2020

Guidelines for clinical trials of psychotropic drugs June 1, 1977

1 reference

12 December 2020

Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study

1 reference

12 December 2020

Methodological issues in psychiatry: psychiatry as an empirical science

1 reference

12 December 2020

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

1 reference

12 December 2020

Are the new antipsychotics no better than the classical neuroleptics? The problematic answer from the CATIE study

1 reference

12 December 2020

The continuing unethical use of placebo controls

1 reference

12 December 2020

Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants?

1 reference

12 December 2020

Clinical features of depressed patients who do and do not improve with placebo

1 reference

12 December 2020

How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials?

1 reference

12 December 2020

Outcome criteria in antidepressant drug trials: self-rating versus observer-rating scales

1 reference

12 December 2020

Isn't the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008.

1 reference

12 December 2020

Standard operating procedure for the registration and computer-supported evaluation of pharmaco-EEG data. 'EEG in Phase I' of the Collegium Internationale Psychiatriae Scalarum (CIPS).

1 reference

12 December 2020

Placebo-controlled trials in major depression are necessary and ethically justifiable: how to improve the communication between researchers and ethical committees.

1 reference

12 December 2020

Guidelines for the implementation of drug utilization observation (DUO) studies in psychopharmacological therapy. The "Phase IV Research" Task-Force of the Association for Neuropsychopharmacology and Pharmacopsychiatry (AGNP).

1 reference

12 December 2020

Placebo-controlled studies in depression: necessary, ethical and feasible

1 reference

12 December 2020

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10

1 reference

12 December 2020

Do effectiveness ("real world") studies on antipsychotics tell us the real truth?

1 reference

12 December 2020

Suicide risk in placebo-controlled studies of major depression

1 reference

12 December 2020

Is a double-blind clinical trial really double-blind? A report of doctors' medication guesses

1 reference

12 December 2020

Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches.

1 reference

12 December 2020

Consensus Conference on the Methodology of Clinical Trials of "Nootropics", Munich, June 1989. Report of the Consensus Committee

1 reference

12 December 2020

Different types of placebo response in patients receiving antidepressants

1 reference

12 December 2020

The AMSP drug safety program: methods and global results

1 reference

12 December 2020

Prediction of therapeutic response in acute treatment with antidepressants. Results of an empirical study involving 159 endogenous depressive inpatients

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Rating depressed patients: observer- vs self-assessment

1 reference

12 December 2020

Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression?

1 reference

12 December 2020

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

1 reference

12 December 2020

Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study.

1 reference

12 December 2020

Placebo response in studies of major depression: variable, substantial, and growing

1 reference

12 December 2020

The AMUP study for drug surveillance in psychiatry - a summary of inpatient data

1 reference

12 December 2020

Problems associated with the classification and diagnosis of psychiatric disorders

1 reference

12 December 2020

Mood curves of neurotic-depressive patients undergoing treatment with antidepressants: time-series analyses of experience with HTAKA model

1 reference

12 December 2020

Design of clinical trials of antidepressants: should a placebo control arm be included?

1 reference

12 December 2020

Standardised rating scales in psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales

1 reference

12 December 2020

Placebo effects on mind and body.

1 reference

12 December 2020

Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression

1 reference

12 December 2020

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

1 reference

12 December 2020

Is there a need for a new psychiatric classification at the current state of knowledge?

1 reference

12 December 2020

Placebo effects in psychiatry.

1 reference

12 December 2020

Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study

1 reference

12 December 2020

10.1007/S00406-009-0071-8

Identifiers

DOI

1 reference

21 August 2017

1 reference